GO
Loading...

Allergan Inc

More

  • Cramer Remix: Warning to the skeptics Tuesday, 18 Nov 2014 | 7:32 PM ET

    "Mad Money" host Jim Cramer issues a warning investors should heed.

  • Cramer: Forget the long game, for now Tuesday, 18 Nov 2014 | 6:11 PM ET

    Jim Cramer just can't make sense of what's happening in the market. Why does it keep going higher? Is it time to stop questioning and jump in?

  • S&P, Dow end at record highs as global worries ease Tuesday, 18 Nov 2014 | 4:52 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Stocks rose on Tuesday, lifting the Dow and S&P 500 to their loftiest ever.

  • Actavis Plc, Gilead Sciences and other biotechs were among the biggest drivers, a day after Allergan agreed to be bought by Actavis. Shares of Actavis were up 8.7 percent at $269.60, helped by bullish analyst notes, while Gilead's stock rose 3.3 percent to $103.71 percent. "A little bit of a risk trade is coming back on, and those are the areas for the M&A," said Uri...

  • Actavis Plc, Gilead Sciences, Celgene and other biotech names were among the S&P 500' s biggest drivers, a day after Allergan agreed to be bought by Actavis. The S&P health care index was up 1.6 percent, while shares of Actavis were up 8.3 percent, Gilead's rose 3.3 percent and shares of Celgene were up 2.4 percent. Helping Actavis were bullish analyst notes.

  • US STOCKS-S&P 500 hits record, healthcare leads gains Tuesday, 18 Nov 2014 | 1:45 PM ET

    Actavis Plc, Gilead, Celgene and other biotech names were among the S&P 500' s biggest drivers, a day after Allergan agreed to be bought by Actavis. The S&P health care index was up 1.4 percent, while shares of Actavis were up 7.7 percent, Gilead's rose 2.9 percent and shares of Celgene were up 2.4 percent. Helping Actavis were bullish analyst notes.

  • Midday movers: Allergan, Apple, Fluor & more Tuesday, 18 Nov 2014 | 12:56 PM ET

    Some of Tuesday midday movers:

  • US STOCKS-S&P 500 hits record again; Actavis rallies Tuesday, 18 Nov 2014 | 11:01 AM ET

    NEW YORK, Nov 18- U.S. stocks rose on Tuesday, lifting the S&P 500 to a record high, boosted by healthcare after Actavis' acquisition of Allergan triggered bullish analyst notes. Allergan on Monday accepted a $66 billion takeover bid from Actavis Plc in cash and stock. At least two analysts raised Actavis' price target, one to as high as $300.

  • Ackman to CNBC: Support Actavis-Allergan deal  Tuesday, 18 Nov 2014 | 10:27 AM ET

    CNBC's David Faber reports investor Bill Ackman has told CNBC he will withdraw from the special meeting on December 18th where Actavis shareholders could have voted on new directors.

  • Ackman has the luck of a loser, to the tune of $2.2B Tuesday, 18 Nov 2014 | 7:02 AM ET
    Bill Ackman

    Heads he wins. Tails he wins. That was the situation Bill Ackman found himself in — or perhaps more accurately, orchestrated — on Monday.

  • Mega-mergers are popular again on Wall Street Tuesday, 18 Nov 2014 | 6:47 AM ET

    Deals worth $100 billion on Monday put the Street on pace for a year rivaling the dot-com bubble era and the private equity surge just before the financial crisis.

  • Hedge funds ditch Apple for AbbVie and Alibaba Tuesday, 18 Nov 2014 | 5:29 AM ET
    A couple look at an Apple Inc. iPhone 6 at an Apple store in the China Central Mall in Beijing, China, on Tuesday, Nov. 11, 2014.

    Hedge funds flocked to Apple ahead of launch of the iPhone 6, but the company is now the most sold position among some of world's largest funds.

  • A day after shock data showing Japan slipping into recession had rattled financial markets, Japan's Nikkei rose 1.7 percent, erasing about a half of Monday's 3.0 percent fall. Prime Minister Shinzo Abe is expected to announce later in the day that he is calling a snap election, banking on the ruling Liberal Democrat Party trouncing a weak opposition to reaffirm...

  • Tracking the Allergan-Actavis merger  Monday, 17 Nov 2014 | 7:32 PM ET

    Sachin Shah, Analyst at Albert Fried and Company, discusses news that botox maker Allergan agreed to a $66 billion takeover bid from Actavis.

  • Cramer Remix: This stock has begun to turn around Monday, 17 Nov 2014 | 7:08 PM ET
    Jim Cramer on Mad Money.

    Wall Street research was ready to give up, but "Mad Money" host Jim Cramer thinks this could be the start of a major turnaround.

  • Cramer: The lucrative journey of Allergan Monday, 17 Nov 2014 | 6:07 PM ET

    Jim Cramer reviews the acquisition of Allergan by Actavis to judge just how lucrative the deal could really be for shareholders.

  • *Baker Hughes rallies, Halliburton tumbles after deal. Shares of Baker Hughes, up 8.9 percent, and Allergan, up 5.3 percent, gave the S&P 500 its biggest boost after Halliburton said it would buy Baker Hughes and Allergan agreed to be bought by Actavis. "It shows the strength of the overall market that you could have this recession news out of Japan, and yet have the...

  • Stocks little moved; S&P 500 at record-high close Monday, 17 Nov 2014 | 4:00 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks fell Monday after data had Japan unexpectedly falling into a recession.

  • Ackman's win-win  Monday, 17 Nov 2014 | 3:18 PM ET

    Actavis announced it will acquire Allergan for $66 billion. Marc LoPresti of Lopresti Law Group, and Michael Farr of Farr, Miller & Washington, discuss Pershing Square Bill Ackman's actions.

  • Nov 17- Botox maker Allergan Inc on Monday accepted a $66 billion takeover bid from Actavis Plc, ending a seven-month hostile pursuit by activist investor William Ackman and Valeant Pharmaceuticals International Inc.. Besides the higher price tag, the Actavis deal came with only $400 million in R&D cuts for Allergan, far less than the $900 million decrease...